Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.

BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.

Canada Pension Plan Investment Board purchased a new position in Vericel Corporation (NASDAQ: VCEL) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,400 shares of the biotechnology company's stock, valued at approximately $596,000. Several other hedge funds and other institutional investors also recently

Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,771 shares of the biotechnology company's stock after buying an additional 180,761 shares during the period. Bank of America Corp DE owned

Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.

Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2026.

Allspring Global Investments Holdings LLC trimmed its position in Vericel Corporation (NASDAQ: VCEL) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 678,003 shares of the biotechnology company's stock after selling 21,710 shares during the quarter. Allspring Global Investments Holdings